Drug Profile
Sotrovimab - GlaxoSmithKline/Vir Biotechnology
Alternative Names: GSK-4182136; VIR-7831; WBP 2275; XevudyLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Vir Biotechnology
- Developer GSK; Vir Biotechnology
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed COVID 2019 infections
Most Recent Events
- 11 Oct 2023 Efficacy and safety data from a phase I COSMIC trial in COVID-2019 infections released by GlaxoSmithKline
- 21 Jul 2023 GlaxoSmithKline and Vir Biotechnology terminates the phase II COMET-PACE trial in COVID-2019 infections (In infants, In neonates, In children, In adolescents, In adults) in the US, Brazil, Greece, Philippines, and South Africa (IM) (IV), due to decrease in in-vitro neutralization of study drug against circulating SARS-CoV-2 variants (NCT05124210) (EudraCT2021-003717-18)
- 14 Jul 2023 National Institute of Allergy and Infectious Diseases completes a phase III trial in COVID-2019 infections (Combination therapy) in United Kingdom, Nigeria, Uganda, Singapore, Denmark, Spain, Switzerland, Greece, USA, Poland (IV) (NCT04501978) (EudraCT2020-003278-37)